[{"Assets_0_Q2_USD":211299000.0,"CommonStockSharesOutstanding_0_Q2_shares":566496400.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-82642000.0,"NetIncomeLoss_1_Q2_USD":-43845000.0,"NetIncomeLoss_2_Q2_USD":-64583000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":9038000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":17234000.0,"Ticker":"ADAP","CIK":"1621227","name":"ADAPTIMMUNE THERAPEUTICS PLC","OfficialName":"Adaptimmune Therapeutics plc American Depositary Shares","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"301181409.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20180802"}]